AUTOLOGOUS MESENCHYMAL STEM CELL THEATMENT FOR PULMONARY FIBROSIS

Patient：81 Years Old Male

Treatment Date：May 2023

 BACKGROUND OF TREATMENT    

The patient, a physician at a hospital in Japan, had a smoking habit and experienced symptoms such as coughing and shortness of breath. Starting in early 2022, he began to feel increasingly fatigued, with a dry cough, shortness of breath, and a loss of appetite, and his symptoms progressively worsened. Despite exhausting all conventional treatment options, the markers for pulmonary fibrosis remained uncontrollable. Upon the recommendation of a professor from Fukuoka University, the patient visited the clinic for autologous mesenchymal stem cell therapy. 

 CHANGES AFTER TREATMENT   

The patient received intravenous injections of autologous stem cells, with 150 million cells per injection, for a total of three sessions. At the start of the first treatment in May 2023, the KL-6 marker was 520. A week after the treatment, the patient’s breathing became noticeably clearer, and his physical strength significantly improved. After three treatments, by November of the same year, the KL-6 marker had dropped to 361, returning to the normal range. Additionally, the patient’s appetite returned, and symptoms such as fatigue, dry cough, and shortness of breath were significantly alleviated. He has maintained normal health status since then. 

* TREATMENT OUTCOMES MAY VARY BY INDIVIDUAL